Innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, including a disease modifying therapy for the treatment of cystic fibrosis.

Has had positive preclinical results and plans to file in Q4 2014 an IND (investigational new drug) with the FDA.

In August 2014, PRQR entered into an agreement with Cystic Fibrosis Foundation Therapeutics to provide PRQR with up to $3 million to support the clinical development of QR-010.

The leading national provider of home- and community-based health and human services to must-serve individuals with intellectual, developmental, physical or behavioral disabilities and other special needs.

Price-to-tangible book value is a negative -1.9, which indicates the private equity owners have stripped as much cash as possible from the company.

A commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions.

The commercial product ATryn, the first and only approved recombinant human antithrombin, has been marketed in the United States since 2009 for the prevention of childbirth blood clots.

Believes the market can be much larger if it can expand ATryn’s FDA-approved label to include additional indications such as the management of preeclampsia.

Medical device company that is designing, developing and commercializing exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again.

As of August 1, 2014, RWLK had placed 62 ReWalk Rehabilitation and 19 ReWalk Personal systems, 88% of which were purchased by RWLK’s customers, and 12% of which were placed.

Cash burn rate is relatively high, indicated by a P/E ratio of -8.9 (lower absolute number is worse).

MCUR is a regenerative medicine company focused on developing, manufacturing and commercializing novel cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds.

RIGP is a growth-oriented limited liability company recently formed by Transocean, one of the world’s largest offshore drilling contractors, to own, operate and acquire modern, technologically advanced offshore drilling rigs.